Guy Goodwin
FMedSci
Emeritus Professor of Psychiatry
The development of better ways to treat mood disorders
My research interests are in the treatment of bipolar disorder and the application of neuroscience and technology in understanding the neurobiology of mood disorders, with a focus on developing new treatments.
I was formerly W.A.Handley Chair of Psychiatry and head of the University department of Psychiatry (1996-2011).
I am a Fellow of the American College of Neuropsychopharmacology, and have previously held the positions of President of the British Association for Psychopharmacology (2004–2005) and of the European College of Neuropsychopharmacology (ECNP, 2013-2016).
I am an Emeritus Senior Investigator on the faculty of UK National Institute for Health Research (NIHR).
I am a Thomson Reuters highly cited researcher (top 1% in field).
Recent publications
-
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Journal article
Goodwin GM. et al, (2023), Neuropsychopharmacology
-
Must Psilocybin Always "Assist Psychotherapy"?
Journal article
Goodwin GM. et al, (2023), Am J Psychiatry
-
A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression
Journal article
Jauhar S. et al, (2023), Molecular Psychiatry
-
Psilocybin for Treatment-Resistant Depression. Reply.
Journal article
Goodwin GM. et al, (2023), N Engl J Med, 388
-
Unblinding and demand characteristics in the treatment of depression.
Journal article
Goodwin GM. et al, (2023), J Affect Disord, 328, 1 - 5